MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100187-PIP01-21-M02)
MHRA-100614-PIP01-22-M01

Scope of the Application

Active Substance(s)

VONICOG ALFA

Condition(s)

Treatment of von Willebrand Disease

Pharmaceutical Form(s)

Powder and solvent for solution for injection

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Baxalta Innovations GmBH

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Baxalta Innovations GmBH submitted to the licensing authority on 08/08/2022 15:34 BST an application for a Modification

The procedure started on 06/03/2023 10:32 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100614-PIP01-22-M01

Of 24/03/2023 13:48 GMT

On the adopted decision for VONICOG ALFA (MHRA-100614-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for VONICOG ALFA, Powder and solvent for solution for injection , INTRAVENOUS USE .

This decision is addressed to Baxalta Innovations GmBH, Industriestrasse 67, Vienna, AUSTRIA, 1221

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of von Willebrand Disease

2.2 Indication(s) targeted by the PIP:

Prevention and treatment of bleeding episodes and for surgical and invasive procedures in paediatric patients (less than 18 years of age) with von Willebrand disease.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Powder and solvent for solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 1 (071102) Open-label study to assess the safety and efficacy of vonicog alfa (rVWF), with or without ADVATE, in the treatment of bleeding episodes, the efficacy and safety of rVWF in elective and emergency surgeries in children diagnosed with severe hereditary VWD and to determine the pharmacokinetics (PK) of rVWF. Study 2 Study deleted in procedure number EMEA-001164-PIP01-11-M01. Study 3 (TAK-577-3001) Study added in procedure number EMEA-001164-PIP01-11-M04. Open-label, uncontrolled study to assess the efficacy and safety vonicog alfa for prophylaxis to prevent or reduce the frequency and/ or severity of bleeding episodes in children with von Willebrand disease.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/12/2025

Deferral of one or more studies contained in the paediatric investigation plan:	Yes